Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- JPMA to Prepare Guidebook on Electronic Data Capture
September 2, 2002
- Monkasho Initiates Protein 3,000 Project
September 2, 2002
- CMIC to Expand Business in Response to New PAL
September 2, 2002
- REGULATORY NEWS IN BRIEF
September 2, 2002
- FJPWA Asks Korosho to Abolish Recording Lot Numbers
September 2, 2002
- Iressa's Price Set by Cost Calculation Method
September 2, 2002
- Tempstaff Dispatches 130 CRAs to Over 10 Drug Companies
September 2, 2002
- WORLD NEWS IN BRIEF
September 2, 2002
- Sankyo Starts e-Promotion
September 2, 2002
- Takara Bio: High-Sensitivity DNA Chip Template "Takara-Hubble Slide"
September 2, 2002
- Schering-Plough Launches Ono's Leukotriene Antagonist Pranlukast in Mexico
September 2, 2002
- Wakamoto: TESTMATE Pylori Antigen EIA before NHI Price Listing
September 2, 2002
- Toyama, Taisho to Respect Each Other's Independence
September 2, 2002
- Hitachi High-Tech to Market bioMerieux's Blood Coagulation Products
September 2, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 2, 2002
- Fujirebio: Half-year Sales Down 4.8% to \12,209 Mil.
September 2, 2002
- General Hospitals' Earnings Up 3 Years in a Row: SWMSC Report
September 2, 2002
- Medical Fee Revision Favors Major Dispensing Pharmacies: Nomura Report
September 2, 2002
- 70% of Patients Don't Like Substitutive Generics: Survey
September 2, 2002
- MEDICAL DEVICE NEWS IN BRIEF
September 2, 2002
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…